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Introduction
Clinical lung transplantation was first performed by
Hardy et al. at Mississippi University in the United States
in 19631), but at that time, all approaches were compro-
mised by severe rejection problems. After the development
of immunosuppressive drugs such as cyclosporine, the first
long-term survival with right unilateral lung transplantation
was reported by Cooper et al. at Toronto University in
Canada in 19832). Currently, either unilateral or bilateral
lung transplantation is routinely performed world wide.
However, because the lung is continuously exposed to the
external environment through the airway, this often pre-
vents potential donor organs from being candidates for
allografting, due to infection, injury to either airway or lung
parenchyma, and adhesion, even when other organs such as
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Background: FUT-175 (nafamostat mesilate) has a variety of pharmacological effects; in addition to its stable potent serine
protease inhibitory activity, it exerts far stronger anti-complement activity than other protease inhibitors. Here, we evaluated
the protective effect of FUT-175 on pulmonary function of xenografts in an ex vivo guinea pig-to-rat lung perfusion model,
using a device for analyzing pulmonary function in small animals.
Methods: Animals were divided into three groups (n = 6 each), Isograft (Group I), Xenograft (Group X), and Xenograft with
FUT-175 (Group XF). In the latter, 10 mg of FUT-175 was added to the extracorporeal circuit before perfusion with xenogeneic
blood was started. The following parameters were serially measured in these three groups: complement activity causing 50%
hemolysis (CH50 units) in the perfusion blood either before or during perfusion, pulmonary arterial pressure, dynamic pulmo-
nary compliance, and airway resistance. In addition, Hematoxylin and Eosin staining of the lungs and assays of rat IgM, IgG,
and anti-C3 deposition were carried out after perfusion.
Results: The duration of satisfactory pulmonary function after the start of perfusion was significantly increased in Group XF.
CH50 in Group XF decreased significantly than in Group X. In addition, FUT-175 suppressed both the increase in pulmonary
arterial pressure and airway resistance, and the decrease in dynamic pulmonary compliance. In Group XF, intraalveolar hem-
orrhage and the thickening of the arterial wall were not observed. Groups X and XF showed deposition of IgM, IgG, and C3
at the endothelium of the pulmonary arteries but less in Group I.
Conclusions: This study suggests that FUT-175 inhibited complement activation including the alternative pathway and im-
proved lung xenograft pulmonary function. FUT-175 ameliorates hyperacute rejection in a guinea pig-to-rat ex vivo xenogeneic
lung perfusion model.
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kidney, or liver from the same donor can be successfully
transplanted. Lack of donor organs has thus been an even
more serious problem in lung transplantation compared to
other organs.
As a solution to the problem of limited organ availability,
xenotransplantation has been a focus of attention recently.
This utilizes animal organs for grafting, and has been studied
extensively worldwide in an effort to translate experimental
systems into clinical utility. Xenotransplantation is classified
into two types. The first is concordant xenotransplantation
between evolutionarily close species such as baboon to
human, and the other is discordant xenotransplantation be-
tween more distant species, such as swine to human and
guinea pig to rat. In discordant combinations, donor organs
usually suffer hyperacute rejection within minutes to hours,
caused by activation of complement induced by natural an-
tibodies against donor cells already present in the recipient
serum. It is mandatory to control this hyperacute rejection for
successful xenotransplantation. Many different approaches to
controlling complement activation have been explored, fo-
cusing either on the host natural antibody or the donor
xenogeneic carbohydrate antigens. This has resulted in the
development of transgenic pigs expressing complement in-
hibitory proteins, used in combination with immunosuppressive
drugs. Recently, carbohydrate xenoantigen-knockout pigs
have also been created and have attracted much attention.
An alternative, or possibly complementary, approach is
described here. The serine protease inhibitor FUT-175
(nafamostat mesilate, Futhan®) exerts several pharmacol-
ogical actions in addition to its protease inhibitory effects.
FUT-175 has potent activity against the C1r and C1s
subunits of the classical pathway, as well as factor B and D
of the alternative pathway3-5). This drug prevents comple-
ment activation in various in vivo experimental models3,6,7).
It has also been demonstrated to contribute to the prolonga-
tion of graft survival in either xenogeneic liver or heart
transplant models8,9).
In the context of lung transplantation, measures of pul-
monary function during acute rejection in allogeneic mod-
els have employed either air content assessment by chest
x-ray or perfusion indices by blood flow scintigraphy.
However, the kinetics of deterioration of xenograft pulmo-
nary function during hyperacute rejection have yet to be
clarified. Here, we have developed an ex vivo guinea pig-
to-rat xenogeneic lung perfusion model using a special
small animal device to analyze pulmonary function. We have
used this model to evaluate the protective effect of FUT-175




Inbred male Lewis rats (Charles river laboratories Japan
Inc., Yokohama, Japan) and outbred male Hartley guinea
pigs (Tagawa laboratory animals Inc., Nagasaki, Japan)
weighing 300 to 350 grams were used in all experiments.
All animals in the study were maintained in accordance
with the guidelines of the Committee of Animal Care of
Nagasaki University School of Medicine, Nagasaki Japan.
The research protocol for the present study was approved
by the Animal Research Studies Committee of Nagasaki
University School of Medicine, Nagasaki Japan (No. 646).
FUT-175
The serine protease inhibitor FUT-175 (Torii Pharmaceutical
Co., Ltd., Tokyo, Japan) could be purchased commercially.
Experimental Design
In this study, animals were divided into three groups
(n = 6 each). In the isograft group (Group I), the left lungs
isolated from Lewis rats were used as donor grafts, while in
the xenograft group (Group X), the left lungs isolated from
guinea pigs were used. In the xenograft + FUT-175 group
(Group XF), 10 mg of FUT-175 was added to the extracorporeal
circulation before perfusion of the xenograft was started.
Ten mg of FUT-175 mixed with 50 mL of blood, yielded
an estimated concentration of 3.7 x 10-4 mol, which is about
6 times the IC50 of complement factor B (6.2 x 10-5 mol), or
about 2.6 times the IC50 of factor D (1.4 x 10-4 mol), and
corresponds to about 100-fold the suggested clinical dose.
Donor Lung Procurement
Lewis rats and Hartley guinea pigs were anesthetized
with intraperitoneal pentobarbital (60 mg/kg), mechanically
ventilated using a rodent respirator (Harvard 683) with
room air (stroke frequency, 90/min, tidal volume, 3 mL/min).
The anterior chest wall was dissected and removed and the
donor animal was heparinized (500 units/kg). The left lung
of the donor was isolated following insertion of a flexible
cannula into the left pulmonary artery and opening of the
left pulmonary vein. Then the lung was connected to the
circuit.
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Design of the lung perfusion circuit (Figure 1)
After priming with heparinized rat blood, the donor graft
was suspended in a sealed chamber, and ventilated with
room air with a tidal volume of 1.5 mL and respiratory rate
of 45 breaths/min. The pulmonary function-analyzing de-
vice, which was connected to the chamber, detected signals
of either airway pressure or flow rate of the ventilated air,
and serially calculated dynamic pulmonary compliance and
airway resistance. For ex vivo perfusion, a flexible tube was
inserted into the left pulmonary artery and connected to the
extracorporeal circulation. The graft was perfused with 50 ml
of heparinized (1000 units/kg) whole blood harvested from
male Lewis rats in all groups at a flow rate of 5 mL/min, at
which rate blood dripped from the free open end of the left
pulmonary vein and was collected in the reservoir by a
roller pump. It was then warmed and recirculated from the
left pulmonary artery by a pump. A deoxygenator was also
set into this circuit, to diffuse a gas mixture of 95% N2 and
5% CO2 at a rate of 1 L/min for deoxygenation of the
blood. Sampling ports were set at both the afferent and ef-
ferent loops of the circuit for blood analysis.
Measured parameters
We serially measured complement activity in the perfu-
sion blood causing 50% hemolysis (CH50 units) before and
during perfusion using CH50 methods reported by Mayer et
al10). Pulmonary arterial pressure (mmHg), dynamic pulmo-
nary compliance (tidal volume/end-inspiratory airway pres-
sure), and airway resistance (mean airway pressure/flow
rate) in each group were also measured. In addition,
hematoxylin and eosin staining and FITC-labeled anti-rat
IgM, IgG, and anti-rat C3 immunofluorescence staining of
the lungs after perfusion were also performed.
Antibodies of immunofluorescence staining
Immunofluorescence staining of rat IgM, IgG and C3 was
performed using FITC labeled goat anti-rat IgM, IgG and
C3 F(ab')2-fragments (American Qualex Inc., San Clemente,
CA).
Statistical analysis
Statistical analyses were performed on a Macintosh com-
puter using Stat View software, version 5.01 (SAS Institute,
NC, USA). Data were shown as mean±standard deviation.
Differences between two groups were analyzed with the
Mann-Whitney U test, and considered to be significant
when probability less than 0.05.
Results
Perfusion time
In both Groups I and XF, the grafts could be perfused for
60 minutes without any increase of mucus secretion in the
airway, while, due to a rapid increase in mucus secretion in
the airway and pulmonary congestion after the initiation of
perfusion, measurements of pulmonary function could not
be continued for more than 15 minutes in Group X. The
measurement periods were thus defined as 60 minutes in
Groups I and XF, but 20 minutes in Group X.
CH50
The time course of CH50, representing total hemolytic
complement activity in the perfusion blood, is shown in
Figure 2. In Groups I and X, it decreased to about 80% of
the preperfusion level after perfusion, and continued to de-
crease gradually thereafter in Group I. On the other hand,
in Group XF, in which FUT-175 was used, there was a
more marked decrease in CH50 to as low as 30% of the
preperfusion level 5 minutes after starting the perfusion,
which was statistically significantly lower than in Group X.
This low level of CH50 was maintained for the 60 minutes
experimental period.
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Figure 1. Schematic diagram of lung perfusion circuit. TV; tidal
volume, RR; ventilated stroke rate, PAP; pulmonary arterial pres-
sure
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PAP index
Pulmonary arterial pressure was analyzed and expressed
as pulmonary arterial pressure index (PAP index; the ratio
relative to the preperfusion value). The PAP index re-
mained the same during the 60 minutes period in Group I,
but increased after perfusion in Group X (1.17 at 5 minutes
and 1.50 at 15 minutes), while it was 0.85 at 5 minutes and
0.73 at 15 minutes in Group XF. This difference was sta-
tistically significant (Figure 3).
Compliance index
Additionally, dynamic pulmonary compliance or airway
resistance was also evaluated as indices relative to preperfusion
values. The compliance index decreased 5 minutes after the
initiation of perfusion and was 0.87 at 15 minutes in Group
X, while it showed no decrease in Group XF (1.17 at 15
minutes). This difference was also statistically significant
(Figure 4).
Airway resistance index
The resistance index increased immediately after perfu-
sion in Group X, but did not change either in Group XF or
Group I (Figure 5). However, these differences did not
reach statistical significance.
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Figure 2. The time course of CH50. CH50 continued to decrease
gradually after perfusion in Groups I and X. It decreased to as low
as 30% of the preperfusion level 5 minutes after starting the per-
fusion in Group XF. This low level of CH50 was maintained for
the 60 minutes.
Figure 3. The time course of PAP (pulmonary arterial pressure)
index; the ratio relative to the preperfusion value. It remained the
same during the 60 minutes period in Group I, but increased after
perfusion in Group X. In Group XF, the PAP index expressed sig-
nificantly lower level compared with the values at 5 and 15 min-
utes in Group X.
Figure 4. The time course of compliance index; the ratio relative
to the preperfusion value. It decreased to 0.87 at 15minutes after
starting the perfusion and the perfusion stopped in Group X. It
showed no decrease and ventilated 60 minutes in Group XF (1.17
at 15 minutes). This difference was statistically significant.
Figure 5. The time course of airway resistance index; the ratio
relative to the preperfusion value. It increased immediately after
perfusion in Group X, but did not change either in Group XF or
Group I during the 60 minutes. These differences did not reach
statistical significance.
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Histological and immunopathological findings
By hematoxylin and eosin and immunofluorescence stain-
ing of the lungs after perfusion, Group I showed no marked
changes in either the alveolus or the arterial lumen (Figure
6a), while in Group X there was either intraalveolar hemor-
rhage or luminal narrowing of arteries due to thickening of
the vascular smooth muscle (Figure 6b), which probably
showing the edema and vasoconstriction. This finding is con-
sistent with previous reports on pulmonary histology during
hyperacute rejection from Tavakoli et al11). In contrast, in
Group XF, intraalveolar hemorrhage was not observed, and
the thickening of the arterial wall was less marked (Figure
6c). However, both Groups X and XF showed deposition of
IgM, IgG, and C3 at the endothelium of the pulmonary ar-
teries but Group I showed less (Figure 7).
Discussion
In allogeneic transplantation, the acute phase problem
consists of ischemia-reperfusion injury, in which excessive
production of inflammatory cytokines by either neutrophils
or macrophages increases tissue factor activity, which in
turn triggers extrinsic coagulation reactions and decreases
the expression of anticoagulants such as thrombomodulin.
The resulting microcirculation insufficiency of transplanted
organs causes graft insufficiency. It was therefore thought
that pulmonary injury after ischemia-reperfusion might be
ameliorated by exploiting the anticoagulation and anti-
inflammatory effects of protease inhibitors. This has been
investigated using gabexelate mesilate (FOY®) and ONO-
5456, a leukocyte elastase inhibitor, in combination with
inhaled nitric oxide, in an experimental model of cadaveric
allogeneic lung transplantation in pigs12,13).
FUT-175, as well as gabexelate mesilate, was developed for
the therapy of acute pancreatitis and disseminated intravascular
coagulation syndrome, and is protease inhibitors showing
anti-complement activity. FUT-175 was shown to have by far
the stronger anti-complement effect compared to gabexelate
mesilate, in both the classical and alternative pathways.
FUT-175 inhibits both C1r and C1s in the classical path-
way, and factor B, factor D, and C3 convertase in the alter-
native pathway in a dose-dependent manner. The IC50 (in-
hibitory concentration 50%) of each enzyme, as given by
the manufacturer, is 1.8 x 10-7 mol for C1r, 2.4 x 10-8 mol
for C1s, 6.2 x 10-5 mol for factor B, and 1.4 x 10-4 mol for
factor D. Here, we used a concentration of 3.7 x 10-4 mol,
which should inhibit even factor D. However, FUT-175 ex-
ists in an ester form with a molecular weight of about 540,
and is easily hydrolyzed in vivo by elastases in either blood
or the liver. It shows biphasic pharmacokinetics with a
serum half-life of about 23 minutes, with an initial rapid
distribution from blood to organs for about 1 minute (distri-
bution phase), and elimination from the body by either me-
tabolism or excretion over about 23 minutes (elimination
phase). The serum concentration thus rapidly decreases if
administered by bolus rather than continuous infusion. On
the other hand, the concentration of FUT-175 in tissues is
higher than in the blood. The elimination half-life of the
unmetabolized form is shortest in the liver (about 7 min-
utes), but is more than 1 hour in the kidney and more than
3 hours in the lung. Miyagawa et al. reported that in the
guinea pig-to-rat heterotopic cardiac xenograft model,
intraperitoneal administration of 20 mg/kg of FUT-175 to
rats suppressed about 80% of C3 activity and almost 100%
of factor B activity, but only about 40% of factor D
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Figure 6. Hematoxylin and eosin staining of the lung after perfu-
sion (x 100). a; Group I showed no marked changes in either the
alveolus or the arteriolar lumen. b; Group X showed either
intraalveolar hemorrhage or luminal narrowing of arterioles due to
thickening of the vascular smooth muscle, which probably show-
ing the edema and vasoconstriction. c; Intraalveolar hemorrhage
was not observed, and the thickening of the arteriolar wall was
less marked in Group XF.
Figure 7. Immunofluorescence study revealed the presence of
IgM, IgG, and C3 deposits on the arteriolar endothelium in both
Group X and XF, but less in Group I (x 400).
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activity, within 1 hour of administration. It was also re-
ported that FUT-175 abrogated ACH50 (reflecting the po-
tency of the alternative pathway) from one to 6 hours after
administration, and prolonged the beating time of heterotopic
heart grafts about 3-fold. This suggests that FUT-175 directly
inhibits serine protease factor B in vivo, which contributes
to the complete abrogation of complement activity and the
prolongation of xenograft survival9).
In the present study, we established a guinea pig-to-rat
ex vivo xenogeneic lung perfusion model, in which we
clearly demonstrated that the perfusion time during which
pulmonary function remained satisfactory was extended
from 15 minutes to more than 60 minutes by FUT-175 in
the perfusion blood. In this ex vivo experimental model, it
cannot be formally excluded that the pharmacokinetics, in-
cluding serum half-life of administered FUT-175, may be
somewhat different from in vivo, and that the results may
not completely reflect the in vivo situation. Nonetheless, in
this model, FUT-175 suppressed both increases in pulmo-
nary arterial pressure and airway resistance, as well as the
decrease in dynamic pulmonary compliance, that were the
results of severe congestion, pulmonary edema and intratracheal
secretions of the rejected lung grafts. These effects may
therefore result not only from suppression of complement
activation (including the alternative pathway), but also the
activation of the coagulation cascade. Kirk et al. reported in
the ex-vivo pig-to-human cardiac xenograft model that
xenoperfused hearts stopped beating by 24 to 34 minutes,
that deposition of IgM, IgG, and C3, as well as cellular in-
filtration by neutrophils, macrophages, and lymphocytes,
was observed in the rejected hearts14). Tavakoli et al. also
reported deposition of IgM, IgG, and C3, as well as cellular
infiltration of lymphocytes, in a guinea pig-to-rat pulmo-
nary xenograft model in which the lungs were rejected at a
mean of 53.3 minutes11). These results imply a contribution
of endothelial injury mediated by leukocytes to the hyperacute
rejection which occurs within minutes. Therefore, the pro-
tective effects of FUT-175 on graft pulmonary functions
observed in the present study are probably also at least
partly mediated via suppressive effects on microcirculation
injury resulting in acute pulmonary injury caused by either
inflammatory cytokines or activation of leukocyte-endothelial
adhesion, or leukocyte elastases.
In conclusion, in an ex vivo xenogeneic lung perfusion
model, administration of FUT-175 to the recipient could
protect the pulmonary functions of donor grafts for a cer-
tain period. In addition to the action of FUT-175 on com-
plement activation during hyperacute rejection, a possible
association with a variety of other pharmacologic functions
was also suggested. Protease inhibitors such as FUT-175
may thus prove useful for effective anti-rejection treatment
in xenogeneic lung transplantation.
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